BioLab Holdings, Inc. Invests in Advanced Antimicrobial Technology
Partnership Will Advance Portable Antimicrobial Solutions for Wound Care and Dermatology
BioLab Holdings, Inc., a leading medical manufacturer based in Phoenix, has announced an exciting new partnership that will greatly enhance healthcare solutions in wound care. The company is proud to reveal its strategic investment collaboration with terraplasma medical GmbH, a German innovator known for developing plasmapax®, a cutting-edge portable cold atmospheric plasma (CAP) device.
The Significance of Cold Atmospheric Plasma Technology
The patented technology behind plasmapax® offers a unique antimicrobial treatment option for various fields, including wound care, dermatology, and podiatry. This innovative approach applies cold plasma generated from atmospheric air, effectively eliminating a wide range of harmful microbes without the use of chemicals, making the treatment both non-invasive and environmentally friendly.
Comments from Industry Leaders
Dr. Christian Zschocke, the majority shareholder of terraplasma medical, expressed enthusiasm regarding the partnership, stating, "BioLab's vision and entrepreneurial spirit aligns perfectly with our goals. We are eager to broaden our reach in critical markets, particularly in the U.S. with our new generation of devices."
Additionally, Jens Kirsch, the Managing Director of terraplasma medical, mentioned, "We believe that BioLab’s extensive product portfolio represents a natural fit with our growth strategy, and we are excited to introduce our technology to the U.S. market."
How the Device Works
The device from terraplasma medical is battery-operated and capable of delivering over 120 treatments per single charge. It utilizes disposable sterile spacers, ensuring a safe and clean application, which is crucial for maintaining hygiene standards in medical settings.
Response from BioLab Leadership
According to BioLab President Jaime Leija, this partnership is a significant leap toward redefining infection control measures. Leija states, "The cold plasma technology developed by terraplasma medical represents a practical and effective solution, which aligns with our mission of providing safer care options for both clinicians and patients."
This state-of-the-art technology has shown impressive results, with over 100,000 treatments completed globally, validating its efficacy and potential. It is CE-marked, backed by decades of scientific research, and poised for further expansion in various healthcare sectors.
FDA Clearance and Future Prospects
Currently, terraplasma medical holds MDR approval in Europe and is working diligently to secure FDA 510(k) clearance in the United States. BioLab’s strategic investment will bolster terraplasma medical's efforts towards regulatory approval and reimbursement pathways, while also facilitating market entry through BioLab's extensive national distribution channels.
Dr. Carlos Encinas, Chief Science Officer at BioLab, remarked, "Cold plasma represents one of the most promising frontiers in the realm of antimicrobial treatment. The technology from terraplasma medical embodies years of research and is now aptly positioned for clinical use. We are excited to be part of its journey towards widespread adoption in the U.S. market."
About BioLab Holdings, Inc. and terraplasma medical GmbH
BioLab Holdings, Inc. specializes in wound healing technologies. The company’s diverse product range, including Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™, and Membrane Wrap - Hydro™, utilizes human tissue allografts derived from amniotic membranes to enhance wound protection mechanisms.
The mission of BioLab is grounded in creating reliable products characterized by the highest quality and continuous innovation, fostering teamwork and superior customer service in healthcare.
terraplasma medical GmbH is at the forefront of applying cold atmospheric plasma technology in medical fields. Their products are designed to merge wound healing properties with strong antimicrobial effects, ensuring top-tier treatments against infections. With robust patent protection and international approvals, terraplasma medical aims to elevate standards in advanced plasma therapies globally.
Contact Information:
Kwyn Lowe
Phone: 406.314.5120
Frequently Asked Questions
What is cold atmospheric plasma technology?
Cold atmospheric plasma technology involves the generation of plasma from atmospheric air, which can effectively kill harmful microbes and is used for treating wounds without chemicals.
Who is partnering with BioLab Holdings?
BioLab Holdings has partnered with terraplasma medical GmbH to advance portable antimicrobial solutions for wound care.
What benefits does the plasmapax® device offer?
The plasmapax® device is non-invasive, easy to use, and can deliver over 120 treatments per charge, utilizing disposable sterile spacers for hygiene.
How many treatments has terraplasma medical completed?
terraplasma medical has conducted over 100,000 treatments globally, validating the effectiveness of its technology.
What are BioLab Holdings' product focuses?
BioLab Holdings focuses on wound care products, including various membranes that utilize human tissue allograft for enhanced healing.
